DMSO is NOT Recommended for Increasing Tissue Perfusion in Skin with Vascular Compromise
Do not use DMSO as a pharmacological agent to improve tissue perfusion or wound healing in patients with vascular compromise. While DMSO has theoretical benefits and some historical use in plastic surgery, current high-quality guidelines explicitly recommend against using pharmacological agents promoting perfusion for wound healing outcomes.
Evidence-Based Rationale
Guideline Recommendations Against Perfusion-Promoting Agents
The most recent and authoritative guidance comes from the 2024 IWGDF guidelines, which provide a strong recommendation against using pharmacological agents promoting perfusion and angiogenesis to improve wound healing outcomes over standard of care 1. This recommendation is based on:
- Nine studies of perfusion-promoting agents showing only small beneficial effects
- Very low certainty of evidence
- Lack of cost-effectiveness data
- Insufficient evidence to justify the resource implications
The balance of effects suggests little difference between intervention or control, making these agents unjustifiable in clinical practice 1.
Limited Context for DMSO Use
DMSO's only guideline-supported role is in chemotherapy extravasation management, not vascular compromise:
- The 2012 ESMO-EONS guidelines describe topical DMSO 99% as a treatment option specifically for anthracycline, mitomycin C, or platinum salt extravasations 2
- Application involves covering twice the affected area, repeated every 8 hours for 1 week
- This indication is entirely separate from treating chronic vascular insufficiency
FDA-Approved Indications
The FDA has approved DMSO only for:
- Interstitial cystitis (intravesical use)
- Organ transplant preservation 3
There is no FDA approval for treating vascular compromise or enhancing tissue perfusion 3.
Clinical Approach to Vascular Compromise
Instead of DMSO, focus on evidence-based interventions:
Immediate Assessment
- Measure ankle-brachial index (ABI) and ankle pressures
- If ankle pressure <50 mmHg or ABI <0.5, obtain urgent vascular imaging 4
- Consider revascularization when appropriate 5, 6
Definitive Treatment
- Revascularization is the cornerstone for critical limb ischemia with tissue loss 5
- Establish in-line blood flow to the foot through endovascular or surgical means 5
- Coordinate wound care with vascular intervention through an interdisciplinary team 5
Adjunctive Measures
- Offload pressure from affected areas
- Manage infection aggressively if present 7
- Optimize cardiovascular risk factors (smoking cessation, blood pressure control, antiplatelet therapy) 4
Important Caveats About DMSO
Safety Concerns
- Can cause lens changes and opacities in animals; requires periodic eye examinations 3
- May initiate histamine liberation and hypersensitivity reactions 3
- Potentiates other concomitantly administered medications 3
- Causes local erythema that can interfere with tissue damage assessment 2
Research vs. Clinical Reality
While older research studies from the 1980s-1990s suggested DMSO might increase flap survival and tissue perfusion in experimental models 8, 9, 10, these findings have not translated into guideline-supported clinical practice for vascular compromise. The 2024 guidelines explicitly reviewed agents promoting perfusion and found insufficient evidence to recommend their use 1.
Mechanism Limitations
Although DMSO has free-radical scavenging properties and theoretical vasodilatory effects 2, 11, improving perfusion in already compromised vasculature requires restoring blood flow mechanically, not pharmacologically. No amount of vasodilation helps if vessels are occluded.
The evidence is clear: pursue revascularization and standard wound care rather than relying on DMSO or other pharmacological perfusion enhancers for vascular compromise 1, 5.